Firestone Capital Management Sells 2,996 Shares of AbbVie Inc. $ABBV

Firestone Capital Management trimmed its stake in AbbVie Inc. (NYSE:ABBV) by 75.5% in the 2nd quarter, HoldingsChannel reports. The firm owned 973 shares of the company’s stock after selling 2,996 shares during the period. Firestone Capital Management’s holdings in AbbVie were worth $245,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently bought and sold shares of ABBV. ACT Advisors LLC. increased its position in AbbVie by 2.5% in the second quarter. ACT Advisors LLC. now owns 1,688 shares of the company’s stock worth $425,000 after buying an additional 41 shares in the last quarter. Willner & Heller LLC lifted its position in shares of AbbVie by 0.7% during the 2nd quarter. Willner & Heller LLC now owns 5,852 shares of the company’s stock valued at $1,472,000 after buying an additional 43 shares in the last quarter. B.O.S.S. Retirement Advisors LLC lifted its position in shares of AbbVie by 3.1% during the 2nd quarter. B.O.S.S. Retirement Advisors LLC now owns 1,427 shares of the company’s stock valued at $359,000 after buying an additional 43 shares in the last quarter. Leslie Global Wealth LLC grew its stake in shares of AbbVie by 1.5% during the 2nd quarter. Leslie Global Wealth LLC now owns 2,983 shares of the company’s stock valued at $751,000 after acquiring an additional 44 shares during the period. Finally, Bank of Jackson Hole Trust grew its stake in shares of AbbVie by 0.6% during the 4th quarter. Bank of Jackson Hole Trust now owns 7,213 shares of the company’s stock valued at $1,648,000 after acquiring an additional 44 shares during the period. 70.23% of the stock is owned by institutional investors.

AbbVie Price Performance

AbbVie stock opened at $261.88 on Friday. The stock has a market cap of $462.69 billion, a P/E ratio of 73.98, a PEG ratio of 0.88 and a beta of 0.30. AbbVie Inc. has a 1 year low of $190.75 and a 1 year high of $267.47. The firm’s 50 day moving average price is $247.72 and its 200-day moving average price is $227.22.

AbbVie (NYSE:ABBV) last issued its earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. The firm had revenue of $16.99 billion during the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. AbbVie’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, equities analysts expect that AbbVie Inc. will post 14.07 EPS for the current year.

AbbVie Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, August 14th. Investors of record on Wednesday, July 15th were given a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date was Wednesday, July 15th. AbbVie’s payout ratio is currently 195.48%.

Analysts Set New Price Targets

A number of equities research analysts have commented on ABBV shares. Wells Fargo & Company raised their target price on shares of AbbVie from $295.00 to $300.00 and gave the stock an “overweight” rating in a research note on Monday. Royal Bank Of Canada increased their price objective on shares of AbbVie from $260.00 to $280.00 and gave the stock an “outperform” rating in a research note on Friday, July 10th. Guggenheim raised their price objective on shares of AbbVie from $261.00 to $288.00 and gave the company a “buy” rating in a research report on Tuesday, August 4th. Erste Group Bank upgraded shares of AbbVie from a “hold” rating to a “buy” rating in a research note on Wednesday, August 5th. Finally, HSBC reaffirmed a “buy” rating and issued a $300.00 target price on shares of AbbVie in a report on Monday, July 6th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $275.95.

Insider Activity at AbbVie

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the transaction, the executive vice president directly owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. This represents a 30.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.06% of the company’s stock.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie reached a new 52-week high. The move above its previous July peak signals continued buying interest and reinforces the stock’s strong uptrend. ABBV is trading well above its 50-day and 200-day moving averages. AbbVie Hits a New 52-Week High
• Positive Sentiment: Analysts and dividend investors remain constructive on ABBV. AbbVie has gained about 19% in 2026, while its $1.73 quarterly dividend provides an annualized payout of $6.92 per share. Recent analyst views include buy ratings and price targets as high as $300, supporting the bullish case. Dividend Giants Pfizer, Chevron, AbbVie
• Positive Sentiment: AbbVie completed a $10 billion senior-notes offering to help fund its Apogee Therapeutics acquisition. The financing supports expansion of AbbVie’s immunology and specialty-medicine pipeline, potentially helping offset future pressure from Humira competition. AbbVie Completes Senior Notes Offering
• Neutral Sentiment: AbbVie paid €370 million in Irish corporation tax last year. The disclosure highlights the company’s significant Irish operations but is unlikely to materially change near-term earnings expectations. AbbVie Irish Corporation Tax
• Negative Sentiment: Executive Vice President Nicholas Donoghoe sold 32,710 ABBV shares for approximately $8.18 million. The transaction reduced his direct holdings by about 30.5%. Although it may reflect personal financial planning, the sizable sale can weigh modestly on sentiment, particularly after the stock’s strong rally. AbbVie Insider Selling
• Negative Sentiment: The Apogee acquisition financing increases AbbVie’s leverage. Investors will evaluate higher interest costs and whether Apogee’s pipeline can generate sufficient returns. ABBV also trades at a high earnings multiple, leaving less room for disappointing results.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.